Thalassemia Market: Global Industry Analysis and Forecast (2021-2027) by Therapeutic Class, Pipeline, and Region

By 2027, the Thalassemia Market is expected to reach US $ 5.58 billion, thanks to growth in the industrial product segment. The report analyzes Thalassemia Market dynamics by region and Pipeline industries.

Thalassemia Market Overview:

Thalassemia is a hereditary (i.e., passed down through the generations) blood illness characterized by the body's inability to produce enough hemoglobin, a key component of red blood cells. When the body's red blood cells don't have enough hemoglobin, they don't function effectively and survive for shorter periods, resulting in fewer healthy red blood cells flowing through the bloodstream. Thalassemia Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2027. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done good in lockdown also and specific strategic analysis of those companies is done in the report

Thalassemia Market Dynamics:

Thalassemia Market size was valued at US$ 2.90 Bn. in 2020 and the total revenue is expected to grow at 9.8% through 2021 to 2027, reaching nearly US$ 5.58 Bn. Thalassemia is a rare genetic blood illness marked by the creation of defective hemoglobin, which causes the loss of red blood cells and results in anemia. Currently, the only therapy choices are blood transfusions and iron chelation therapies. This creates a plethora of market prospects for the development of a universal thalassemia treatment. According to the Thalassemia International Federation, around 7.0 % of the world's population is affected by hemoglobin-related diseases and ailments, with 70.0 % having sickle cell anemia and the rest developing thalassemia or other blood disorders. Around 2.1 percent of the world's population has thalassemia in one form or another. Around 4.4 out of every 10,000 live births in the world are affected by this condition. Greece, Turkey's coastal regions, some portions of Italy, important Mediterranean islands like Cyprus, and South Asian countries like the Maldives and India are the most affected. Thalassemia is an orphan or rare disease in the United States, affecting fewer than 20,000 people. The tropical regions, such as Nigeria, Sudan, Chad, Columbia, and a few South Asian countries, are more likely to have significant numbers of patients with alpha thalassemia. Research institutes and pharmaceutical businesses, expanding alpha thalassemia testing usage and technological improvements, and increased awareness are some of the reasons driving the region's alpha thalassemia market expansion. A large number of alpha thalassemia patients can be found in a few Asian nations, such as Myanmar and Thailand.

Thalassemia Market Segment Analysis:

The Iron Chelating Drugs segment is dominating the Therapeutic Class segment of the Thalassemia Market:

Thalassemia is currently managed by symptomatic treatment rather than cure. Iron overload from blood transfusions, vitamin supplements, fetal hemoglobin raising medications, and indicaxanthin, an antioxidant that prevents hemoglobin breakdown, are among the most common treatments for the illness. If medications now in phase II/III trial pipeline achieve regulatory approval, the market for thalassemia treatments is projected to be quite lucrative. In developed regions such as North America and Europe, the market is driven by increased awareness of existing treatment modalities and the launch of novel treatment approaches. In addition, demand for thalassemia medications and treatments is expected to rise in growing markets such as India and Pakistan in the next years due to a huge youth population.

The Gene Therapy segment is leading the Pipeline segment of the Thalassemia Market:

With multiple genomic products in late-stage studies, gene therapy is likely to be a huge success among other developing curative medicines. For the treatment of thalassemia, there are currently 15 pipeline drugs in clinical studies. The majority of these items are based on gene therapy and are aimed at curing the disease. In addition, the top-line main and secondary endpoint findings from these medications' clinical trials were positive. Despite major clinical development obstacles and regulatory uncertainty, gene therapy has the potential to transform the thalassemia therapeutic landscape.

Thalassemia Market Regional Insights:

North America is estimated to dominate the growth of the Thalassemia Market. Throughout the projected period, North America is expected to dominate the global thalassemia treatment market. Factors such as the existence of important companies, the high prevalence of thalassemia patients in the region, and established healthcare infrastructure are some of the key factors responsible for the market's huge share. Furthermore, favorable government efforts and an increase in the number of research partnerships are projected to propel the market forward. The United States has the largest percentage due to increased knowledge of the disorder, an increase in the number of people with the thalassemia carrier gene, and an increase in birth rates due to population genetic variation. Thalassemia Market by Regional The objective of the report is to present a comprehensive analysis of the Thalassemia Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Thalassemia Market dynamics, structure by analyzing the market segments and projecting the Thalassemia Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Thalassemia Market make the report investor’s guide.

Thalassemia Market Scope: Inquire before buying

Thalassemia Market by Scope

Thalassemia Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Thalassemia Market Key Player

• bluebird bio, Inc. • Acceleron Pharma, Inc. • Celgene Corporation • GlaxoSmithKline plc • Incyte Corporation • Gamida Cell • Kiadis Pharma • La Jolla Pharmaceutical Company • IONIS Pharmaceuticals • Acceleron Pharma • Novartis AG • Pharmaceuticals Inc • Alnylam Pharmaceuticals Inc • Calimmune Inc • CRISPR Therapeutics • Editas Medicine Inc • Errant Gene Therapeutics LLC • Gamida Cell Ltd • Gilead Sciences Inc • Incyte Corp • Ionis Pharmaceuticals Inc

FAQs:

1. What is the Thalassemia Market value in 2020? Ans: Thalassemia Market value in 2020 was estimated as 2.90 Billion USD. 2. What is the Thalassemia Market growth? Ans: The Thalassemia Market is anticipated to grow with a CAGR of 9.8% in the forecast period and is likely to reach USD 5.58 Billion by the end of 2027. 3. Which segment is expected to dominate the Thalassemia Market during the forecast period? Ans: North America is expected to dominate the global thalassemia treatment market. Factors such as the existence of important companies, the high prevalence of thalassemia patients in the region, and established healthcare infrastructure are some of the key factors responsible for the market's huge share. 4. Who are the key players in the Thalassemia Market? Ans: Some key players operating in the thalassemia market include bluebird bio, Inc.; Acceleron Pharma, Inc.; Celgene Corporation; GlaxoSmithKline plc; Incyte Corporation; Gamida Cell; Kiadis Pharma; La Jolla Pharmaceutical Company; and IONIS Pharmaceuticals. 5. What is the key driving factor for the growth of the Thalassemia Market? Ans: Key factors that are driving the market growth include an increase in awareness about available treatment options and a rise in demand for improved curative gene therapies.
1. Global Thalassemia Market: Research Methodology 2. Global Thalassemia Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Thalassemia Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Thalassemia Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Thalassemia Market Segmentation 4.1 Global Thalassemia Market, by Therapeutic Class (2020-2027) • Iron Chelating Drugs o Exjade/Jadenu (deferasirox) • Blood Transfusions • Folic Acid Supplements • Others 4.2 Global Thalassemia Market, by Pipeline (2020-2027) • Gene Therapy o LentiGlobin 5. North America Thalassemia Market (2020-2027) 5.1 North America Thalassemia Market, by Therapeutic Class (2020-2027) • Iron Chelating Drugs o Exjade/Jadenu (deferasirox) • Blood Transfusions • Folic Acid Supplements • Other 5.2 Global Thalassemia Market, by Pipeline (2020-2027) • Gene Therapy o LentiGlobin 5.3 North America Thalassemia Market, by Country (2020-2027) • United States • Canada • Mexico 6. Asia Pacific Thalassemia Market (2020-2027) 6.1. Asia Pacific Thalassemia Market, by Therapeutic Class (2020-2027) 6.2. Asia Pacific Thalassemia Market, by Pipeline (2020-2027) 6.2. Asia Pacific Thalassemia Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Thalassemia Market (2020-2027) 7.1. Middle East and Africa Thalassemia Market, by Therapeutic Class (2020-2027) 7.2. Middle East and Africa Thalassemia Market, by Pipeline (2020-2027) 7.3. Middle East and Africa Thalassemia Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Thalassemia Market (2020-2027) 8.1. Latin America Thalassemia Market, by Therapeutic Class (2020-2027) 8.2. Latin America Thalassemia Market, by Pipeline (2020-2027) 8.3 Latin America Thalassemia Market, by Country (2020-2027) • Brazil • Argentina • Rest of Latin America 9. European Thalassemia Market (2020-2027) 9.1. European Thalassemia Market, by Therapeutic Class (2020-2027) 9.2. European Thalassemia Market, by Pipeline (2020-2027) 9.3 European Thalassemia Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. Veolia 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. bluebird bio, Inc. 10.3. Acceleron Pharma, Inc. 10.4. Celgene Corporation 10.5. GlaxoSmithKline plc 10.6. Incyte Corporation 10.7. Gamida Cell 10.8. Kiadis Pharma 10.9. La Jolla Pharmaceutical Company 10.10. IONIS Pharmaceuticals 10.11. Acceleron Pharma 10.12. Novartis AG 10.13. Pharmaceuticals Inc 10.14. Alnylam Pharmaceuticals Inc 10.15. Calimmune Inc 10.16. CRISPR Therapeutics 10.17. Editas Medicine Inc 10.18. Errant Gene Therapeutics LLC 10.19. Gamida Cell Ltd 10.20. Gilead Sciences Inc 10.21. Incyte Corp 10.22. Ionis Pharmaceuticals Inc

About This Report

Report ID126529
Category Healthcare
Published DateNov 2021
Updated Date
Contact Us